rituximab-alliinase conjugate

alliinase conjugated to the monoclonal antibody rituximab, which recognizes the CD20 antigen, and the resulting conjugate was targeted to CD20+ B chronic lymphocytic leukemia (B-CLL) and other B-cell lymphomas

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Arditti, Fabian D: 1 article (02/2005)
2.	Berrebi, Alain: 1 article (02/2005)
3.	Mirelman, David: 1 article (02/2005)
4.	Miron, Talia: 1 article (02/2005)
5.	Rabinkov, Aharon: 1 article (02/2005)
6.	Reisner, Yair: 1 article (02/2005)
7.	Wilchek, Meir: 1 article (02/2005)

Related Diseases

1.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/01/2005 - "Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate."
2.	Neoplasms (Cancer) 02/01/2005 - "Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate."

Related Drugs and Biologics

1.	allicin